{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T20:21:57Z","timestamp":1787862117592,"version":"build-2784847793"},"reference-count":22,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T00:00:00Z","timestamp":1783382400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.clml.2026.07.001","type":"journal-article","created":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T15:39:32Z","timestamp":1783525172000},"page":"595-608.e3","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Dose Optimization of Dasatinib in Chronic-Phase Chronic Myeloid Leukemia: A Systematic Review and Meta-analysis of 50 mg Versus 100 mg Once Daily"],"prefix":"10.1016","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0622-8455","authenticated-orcid":false,"given":"Mohammed","family":"Abdulgayoom","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-0577-7295","authenticated-orcid":false,"given":"Motaz","family":"Almahmood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rasha","family":"Kaddoura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rowan","family":"Mesilhy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8207-047X","authenticated-orcid":false,"given":"Rita","family":"Ahmad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad S.","family":"Afana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-7579-4923","authenticated-orcid":false,"given":"Ayman Abdullah","family":"Dalol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Awni","family":"Alshurafa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdulrahman F.","family":"Al-Mashdali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Yassin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shehab F.","family":"Mohamed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.clml.2026.07.001_bib0001","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1038\/s41375-020-0776-2","article-title":"European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia","volume":"34","author":"Hochhaus","year":"2020","journal-title":"Leukemia"},{"issue":"24","key":"10.1016\/j.clml.2026.07.001_bib0002","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1056\/NEJMoa1002315","article-title":"Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia","volume":"362","author":"Kantarjian","year":"2010","journal-title":"N Engl J Med"},{"issue":"20","key":"10.1016\/j.clml.2026.07.001_bib0003","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1200\/JCO.2015.64.8899","article-title":"Final 5-year study results of DASISION: the dasatinib versus imatinib study in treatment-naive chronic myeloid leukemia patients trial","volume":"34","author":"Cortes","year":"2016","journal-title":"J Clin Oncol"},{"issue":"13","key":"10.1016\/j.clml.2026.07.001_bib0004","doi-asserted-by":"crossref","first-page":"2740","DOI":"10.1002\/cncr.31357","article-title":"Early results of lower dose dasatinib (50 mg daily) as frontline therapy for newly diagnosed chronic-phase chronic myeloid leukemia","volume":"124","author":"Naqvi","year":"2018","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.clml.2026.07.001_bib0005","doi-asserted-by":"crossref","first-page":"17","DOI":"10.2169\/internalmedicine.9035-17","article-title":"The efficacy of reduced-dose dasatinib as a subsequent therapy in patients with chronic myeloid leukemia in the chronic phase: the LD-CML study of the Kanto CML Study Group","volume":"57","author":"Iriyama","year":"2018","journal-title":"Intern Med"},{"issue":"1","key":"10.1016\/j.clml.2026.07.001_bib0006","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1002\/cncr.32504","article-title":"Long-term follow-up of lower dose dasatinib (50 mg daily) as frontline therapy in newly diagnosed chronic-phase chronic myeloid leukemia","volume":"126","author":"Naqvi","year":"2020","journal-title":"Cancer"},{"issue":"11","key":"10.1016\/j.clml.2026.07.001_bib0007","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1002\/ajh.26689","article-title":"Low-dose dasatinib 50 mg\/day versus standard-dose dasatinib 100 mg\/day as frontline therapy in chronic myeloid leukemia in chronic phase: a propensity score analysis","volume":"97","author":"Jabbour","year":"2022","journal-title":"Am J Hematol"},{"issue":"2","key":"10.1016\/j.clml.2026.07.001_bib0008","doi-asserted-by":"crossref","DOI":"10.1016\/j.clml.2022.11.006","article-title":"Attenuated dose dasatinib in newly diagnosed chronic myeloid leukemia chronic phase patients in India","volume":"23","author":"Ahmed","year":"2023","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"10","key":"10.1016\/j.clml.2026.07.001_bib0009","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.clml.2023.05.009","article-title":"Low-dose dasatinib (50 mg daily) frontline therapy in newly diagnosed chronic phase chronic myeloid leukemia: 5-year follow-up results","volume":"23","author":"Gener-Ricos","year":"2023","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2026.07.001_bib0010","article-title":"Study on efficacy and safety of dasatinib 50 mg in newly diagnosed patients of chronic myeloid leukemia (CML) in chronic phase (CP): experience from a tertiary care hospital","author":"Banerjee","year":"2025","journal-title":"Indian J Hematol Blood Transfus"},{"issue":"1","key":"10.1016\/j.clml.2026.07.001_bib0011","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1186\/s12885-026-15719-7","article-title":"Efficacy and safety of 50 mg versus 100 mg daily frontline dasatinib therapy in chronic-phase chronic myeloid leukemia: a non-controlled, observational dose-comparative cohort study","volume":"26","author":"Cheng","year":"2026","journal-title":"BMC Cancer"},{"key":"10.1016\/j.clml.2026.07.001_bib0012","article-title":"Real-world outcomes with low-dose dasatinib (50 mg) in imatinib-resistant chronic myeloid leukemia in chronic phase: a retrospective analysis of efficacy and safety","volume":"9","author":"Gangadaran","year":"2026","journal-title":"Cancer Rep (Hoboken)"},{"key":"10.1016\/j.clml.2026.07.001_bib0013","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.clml.2026.07.001_bib0014","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"issue":"7414","key":"10.1016\/j.clml.2026.07.001_bib0015","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1016\/j.clml.2026.07.001_bib0016","series-title":"R: a language and environment for statistical computing","year":"2025"},{"issue":"3","key":"10.1016\/j.clml.2026.07.001_bib0017","first-page":"40","article-title":"Meta: an R package for meta-analysis","volume":"7","author":"Schwarzer","year":"2007","journal-title":"R News"},{"issue":"3","key":"10.1016\/j.clml.2026.07.001_bib0018","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v036.i03","article-title":"Conducting meta-analyses in R with the metafor package","volume":"36","author":"Viechtbauer","year":"2010","journal-title":"J Stat Softw"},{"issue":"5","key":"10.1016\/j.clml.2026.07.001_bib0019","doi-asserted-by":"crossref","first-page":"e678","DOI":"10.1016\/j.clml.2026.02.013","article-title":"Outcomes of patients treated with dasatinib 50 mg\/day: a pooled analysis","volume":"26","author":"Haddad","year":"2026","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"6","key":"10.1016\/j.clml.2026.07.001_bib0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.clml.2021.01.020","article-title":"Appropriate starting dose of dasatinib based on analyses of dose-limiting toxicities and molecular responses in Asian patients with chronic myeloid leukemia","volume":"21","author":"Shin","year":"2021","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"10","key":"10.1016\/j.clml.2026.07.001_bib0021","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1007\/s11095-023-03603-z","article-title":"Population pharmacokinetics and pharmacogenetics analyses of dasatinib in Chinese patients with chronic myeloid leukemia","volume":"40","author":"He","year":"2023","journal-title":"Pharm Res"},{"issue":"7","key":"10.1016\/j.clml.2026.07.001_bib0022","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1080\/17474086.2024.2370556","article-title":"Is 50 mg\/day the new standard dose of dasatinib in newly diagnosed patients with chronic myeloid leukemia in chronic phase?","volume":"17","author":"Saydan","year":"2024","journal-title":"Exp Rev Hematol"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265026002065?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265026002065?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T19:47:21Z","timestamp":1787860041000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265026002065"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":22,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S2152265026002065"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2026.07.001","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dose Optimization of Dasatinib in Chronic-Phase Chronic Myeloid Leukemia: A Systematic Review and Meta-analysis of 50 mg Versus 100 mg Once Daily","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2026.07.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}